|
US4350687A
(en)
|
1980-02-10 |
1982-09-21 |
Research Corporation |
Platelet derived cell growth factor
|
|
JPS60146833A
(ja)
|
1984-01-10 |
1985-08-02 |
Green Cross Corp:The |
モノクロ−ナル抗体製剤
|
|
JPS6178731A
(ja)
|
1985-05-20 |
1986-04-22 |
Green Cross Corp:The |
加熱処理免疫グロブリン製剤
|
|
CA1327161C
(en)
|
1987-09-01 |
1994-02-22 |
Mitsugu Kobayashi |
Lyophilized pharmaceutical composition of neocarzinostatin derivative
|
|
SE8801537D0
(sv)
|
1988-04-26 |
1988-04-26 |
Ellco Food Ab |
Cellodlingsmedium samt forfarande for dess framstellning
|
|
US5252713A
(en)
|
1988-09-23 |
1993-10-12 |
Neorx Corporation |
Polymeric carriers for non-covalent drug conjugation
|
|
JPH04504253A
(ja)
|
1989-03-27 |
1992-07-30 |
セントカー・インコーポレーテツド |
ＩｇＭ抗体の安定化のための配合物
|
|
US5116944A
(en)
|
1989-12-29 |
1992-05-26 |
Neorx Corporation |
Conjugates having improved characteristics for in vivo administration
|
|
US5216130A
(en)
|
1990-05-17 |
1993-06-01 |
Albany Medical College |
Complex for in-vivo target localization
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5260308A
(en)
|
1991-11-06 |
1993-11-09 |
Mayo Foundation For Medical Education And Research |
Method to increase permeability of the blood-nerve/brain barriers to proteins
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
|
PT910382E
(pt)
|
1996-04-26 |
2003-10-31 |
Genaera Corp |
Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
|
|
GB9613182D0
(en)
|
1996-06-24 |
1996-08-28 |
Nycomed Imaging As |
Method
|
|
US6416967B2
(en)
|
1996-07-12 |
2002-07-09 |
Precision Therapeutics, Inc. |
Method of using multicellular particulates to analyze malignant or hyperproliferative tissue
|
|
US5728541A
(en)
|
1996-07-12 |
1998-03-17 |
Precision Therapeutics, Inc. |
Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
|
|
KR100904931B1
(ko)
|
1997-06-27 |
2009-06-29 |
아브락시스 바이오사이언스, 엘엘씨 |
나노 입자 및 그의 제조 방법
|
|
US8853260B2
(en)
|
1997-06-27 |
2014-10-07 |
Abraxis Bioscience, Llc |
Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
US7041301B1
(en)
|
1997-11-07 |
2006-05-09 |
Mayo Foundation For Medical Education And Research |
Interferon immunotherapy
|
|
US6616925B1
(en)
|
1998-04-02 |
2003-09-09 |
I.D.M. Immuno-Designed Molecules |
Combined preparation for the treatment of neoplasic diseases or of infectious diseases
|
|
US7112409B2
(en)
|
1999-01-29 |
2006-09-26 |
Center For Molecular Medicine And Immunology |
Method of determining cytokine dosage for myelosuppressive state
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US6420378B1
(en)
|
1999-10-15 |
2002-07-16 |
Supergen, Inc. |
Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
|
|
DE10132502A1
(de)
|
2001-07-05 |
2003-01-23 |
Gsf Forschungszentrum Umwelt |
Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
|
|
PT1503794E
(pt)
|
2002-04-12 |
2012-06-21 |
Medarex Inc |
Métodos de tratamento usando anticorpos contra ctla-4
|
|
IL166156A0
(en)
|
2002-07-09 |
2006-01-15 |
Point Therapeutics Inc |
Boroproline compound combination therapy
|
|
JP4596916B2
(ja)
|
2002-09-05 |
2010-12-15 |
メディミューン，エルエルシー |
Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
|
|
US8034334B2
(en)
|
2002-09-06 |
2011-10-11 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
|
|
SI1585548T1
(sl)
|
2002-12-09 |
2018-11-30 |
Abraxis Bioscience, Llc |
Sestave in metode odmerjanja farmakoloških sredstev
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
ATE459364T1
(de)
|
2003-10-22 |
2010-03-15 |
Univ Johns Hopkins |
Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren
|
|
ATE401088T1
(de)
|
2004-04-22 |
2008-08-15 |
Lilly Co Eli |
Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs
|
|
ES2662848T3
(es)
*
|
2004-05-14 |
2018-04-10 |
Abraxis Bioscience, Llc |
Composiciones farmacéuticas de suministro en el sitio de enfermedad que comprenden paclitaxel
|
|
US20060067930A1
(en)
*
|
2004-08-19 |
2006-03-30 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
WO2006034455A2
(en)
|
2004-09-23 |
2006-03-30 |
Vasgene Therapeutics, Inc. |
Polipeptide compounds for inhibiting angiogenesis and tumor growth
|
|
CN101438252A
(zh)
|
2004-10-07 |
2009-05-20 |
爱莫里大学 |
多功能纳米粒子共轭体及其应用
|
|
KR20190062506A
(ko)
|
2005-02-18 |
2019-06-05 |
아브락시스 바이오사이언스, 엘엘씨 |
치료제의 조합 및 투여 방식, 및 조합 요법
|
|
US20070166388A1
(en)
|
2005-02-18 |
2007-07-19 |
Desai Neil P |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
US8735394B2
(en)
*
|
2005-02-18 |
2014-05-27 |
Abraxis Bioscience, Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
CN103285392A
(zh)
|
2005-04-26 |
2013-09-11 |
卫材R&D管理株式会社 |
用于癌症免疫疗法的组合物和其用途
|
|
US10183076B2
(en)
|
2005-05-16 |
2019-01-22 |
Resdevco Research And Development Co. L |
Topical compositions for treatment of irritation of mucous membranes
|
|
NZ592132A
(en)
|
2005-08-31 |
2012-12-21 |
Abraxis Bioscience Llc |
Composition comprising nanoparticles of docitaxel and a citrate
|
|
RU2433818C2
(ru)
|
2005-08-31 |
2011-11-20 |
АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи |
Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества
|
|
US7776832B2
(en)
|
2006-04-21 |
2010-08-17 |
Gem Pharmaceuticals, Llc |
Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
|
|
LT2081595T
(lt)
|
2006-09-26 |
2019-07-10 |
Genmab A/S |
Anti-cd38 plius kortikosteroidai, plius nekortikosteroidinis chemoterapinis agentas, skirti vėžio gydymui
|
|
BRPI0717634A2
(pt)
|
2006-10-17 |
2013-10-29 |
Koninkl Philips Electronics Nv |
Dispositivo para amplificação e detecção de ácidos nucleicos, sistema para amplificação e detecção de ácidos nucléicos, e, método para detectar hibridização em tempo real de ácidos nucleicos para uma sonda de captura
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
GB0621973D0
(en)
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
|
US20100112077A1
(en)
*
|
2006-11-06 |
2010-05-06 |
Abraxis Bioscience, Llc |
Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
|
|
MX2009004829A
(es)
*
|
2006-11-07 |
2009-07-24 |
Dow Agrosciences Llc |
Formulacion para tecnica de aniquilacion de machos (mat) para rociar, con liberacion controlada, y metodo de control de insectos.
|
|
NZ578329A
(en)
|
2006-12-13 |
2012-05-25 |
Schering Corp |
Igf1r inhibitors for treating cancer
|
|
PT2481409T
(pt)
|
2007-03-07 |
2018-10-18 |
Abraxis Bioscience Llc |
Nanopartícula que compreende rapamicina e albumina como agente anticancerígeno
|
|
US20100047234A1
(en)
|
2007-03-14 |
2010-02-25 |
Markovic Svetomir N |
Treating skin cancer
|
|
WO2009005673A1
(en)
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Anti-igf1r
|
|
US20100287638A1
(en)
|
2007-10-01 |
2010-11-11 |
The Hospital For Sick Children |
Neural tumor stem cells and methods of use thereof
|
|
CN101918579A
(zh)
|
2007-10-22 |
2010-12-15 |
先灵公司 |
完全人抗-vegf抗体和使用方法
|
|
CA2705152C
(en)
|
2007-11-09 |
2016-10-11 |
Peregrine Pharmaceuticals, Inc. |
Anti-vegf antibody compositions and methods
|
|
EP2310006A4
(en)
|
2008-07-03 |
2012-04-25 |
Mayo Foundation |
CANCER TREATMENT
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
US20110293576A1
(en)
|
2008-08-04 |
2011-12-01 |
Allocure Inc. |
Mesenchymal stromal cell populations and methods of isolating and using same
|
|
WO2010075540A1
(en)
|
2008-12-23 |
2010-07-01 |
Burnham Institute For Medical Research |
Methods and compositions for synaphically-targeted treatment for cancer
|
|
JP5851842B2
(ja)
|
2009-01-12 |
2016-02-03 |
サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. |
改変した抗体組成物、それを作製および使用する方法
|
|
US9636384B2
(en)
|
2009-04-06 |
2017-05-02 |
Mayo Foundation For Medical Education And Research |
Methods for making polymeric nanoparticle-polypeptide complex
|
|
EP2416650B1
(en)
|
2009-04-10 |
2020-02-26 |
Abraxis BioScience, LLC |
Nanoparticle formulations and uses therof
|
|
US8571805B2
(en)
|
2009-04-10 |
2013-10-29 |
Pharmaco-Kinesis Corporation |
Method and apparatus for detecting and regulating vascular endothelial growth factor (VEGF) by forming a homeostatic loop employing a half-antibody biosensor
|
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
UY32665A
(es)
|
2009-05-28 |
2010-12-31 |
Glaxo Group Ltd |
Proteinas de union al antigeno
|
|
US8345535B2
(en)
*
|
2009-07-13 |
2013-01-01 |
Lg Electronics Inc. |
Method and apparatus for generating ranging preamble code in wireless communication system
|
|
AR078161A1
(es)
*
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
KR20120101050A
(ko)
|
2009-11-05 |
2012-09-12 |
더 유에이비 리서치 파운데이션 |
기저형 유전자형 암의 치료 방법
|
|
US20120263739A1
(en)
|
2009-11-13 |
2012-10-18 |
Merck Patent Gmbh |
Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents
|
|
US20120294852A1
(en)
*
|
2009-11-24 |
2012-11-22 |
Smith Jeffrey T L |
Antagonists of il-6 to raise albumin and/or lower crp
|
|
KR20130009760A
(ko)
*
|
2010-02-10 |
2013-01-23 |
이뮤노젠 아이엔씨 |
Ｃｄ２０ 항체 및 이의 용도
|
|
EP3056201A1
(en)
|
2010-06-07 |
2016-08-17 |
Abraxis BioScience, LLC |
Combination therapy methods for treating proliferative diseases
|
|
US9466148B2
(en)
|
2010-09-03 |
2016-10-11 |
Disney Enterprises, Inc. |
Systems and methods to dynamically adjust an image on a display monitor represented in a video feed
|
|
US20130281376A1
(en)
*
|
2010-10-08 |
2013-10-24 |
Abraxis Bioscience, Llc |
Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer
|
|
WO2012071561A2
(en)
*
|
2010-11-23 |
2012-05-31 |
Alder Biopharmaceuticals, Inc. |
Anti-il-6 antibodies for the treatment of anemia
|
|
US20130281377A1
(en)
|
2010-12-23 |
2013-10-24 |
Mayo Foundation For Medical Education And Research |
Treating multiple myeloma
|
|
US9427477B2
(en)
*
|
2011-05-09 |
2016-08-30 |
Mayo Foundation For Medical Education And Research |
Cancer treatments
|
|
US20130028895A1
(en)
|
2011-07-27 |
2013-01-31 |
Gerald Wulf |
Exosome inhibiting agents and uses thereof
|
|
AU2013201121A1
(en)
|
2011-09-20 |
2013-04-04 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
JP6149042B2
(ja)
|
2011-11-09 |
2017-06-14 |
ザ ユーエービー リサーチ ファンデーション |
Ｈｅｒ３抗体およびその使用
|
|
US11471486B2
(en)
|
2012-09-04 |
2022-10-18 |
Inven2 As |
Selective and controlled expansion of educated NK cells
|
|
AU2013327638B2
(en)
|
2012-10-01 |
2018-06-14 |
Mayo Foundation For Medical Education And Research |
Cancer treatments
|
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
|
US20140186447A1
(en)
|
2012-12-28 |
2014-07-03 |
Abraxis Bioscience, Llc |
Nanoparticle compositions of albumin and paclitaxel
|
|
PE20160541A1
(es)
|
2013-09-27 |
2016-06-03 |
Genentech Inc |
Formulaciones de anticuerpos anti-pdl1
|
|
MX380597B
(es)
|
2014-06-13 |
2025-03-12 |
Mayo Found Medical Education & Res |
Composición con complejos de nanopartículas/anticuerpos de paclitaxel unidos a albúmina para usarse al tratar linfoma.
|
|
US10213513B2
(en)
|
2014-06-16 |
2019-02-26 |
Mayo Foundation For Medical Education And Research |
Treating myelomas
|
|
US9446148B2
(en)
|
2014-10-06 |
2016-09-20 |
Mayo Foundation For Medical Education And Research |
Carrier-antibody compositions and methods of making and using the same
|
|
EA201790248A1
(ru)
|
2014-10-06 |
2017-07-31 |
Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч |
Композиции носитель-антитело и способы их получения и применения
|
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
|
EP3226856A4
(en)
|
2014-12-02 |
2018-07-11 |
Celgene Corporation |
Combination therapies
|
|
TW201707725A
(zh)
|
2015-08-18 |
2017-03-01 |
美國馬友醫藥教育研究基金會 |
載體－抗體組合物及其製造及使用方法
|
|
WO2017176265A1
(en)
|
2016-04-06 |
2017-10-12 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
WO2017031368A1
(en)
|
2015-08-18 |
2017-02-23 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
TW201713360A
(en)
|
2015-10-06 |
2017-04-16 |
Mayo Foundation |
Methods of treating cancer using compositions of antibodies and carrier proteins
|
|
WO2017120501A1
(en)
|
2016-01-07 |
2017-07-13 |
Mayo Foundation For Medical Education And Research |
Methods of treating cancer with interferon
|
|
US11351254B2
(en)
|
2016-02-12 |
2022-06-07 |
Mayo Foundation For Medical Education And Research |
Hematologic cancer treatments
|
|
US11878061B2
(en)
|
2016-03-21 |
2024-01-23 |
Mayo Foundation For Medical Education And Research |
Methods for improving the therapeutic index for a chemotherapeutic drug
|
|
WO2017165440A1
(en)
|
2016-03-21 |
2017-09-28 |
Mayo Foundation For Medical Education And Research |
Methods for reducing toxicity of a chemotherapeutic drug
|
|
US10618969B2
(en)
|
2016-04-06 |
2020-04-14 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
|
JP7158372B2
(ja)
|
2016-08-05 |
2022-10-21 |
マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ |
癌治療のための修飾抗体－アルブミンナノ粒子複合体
|
|
US11548946B2
(en)
|
2016-09-01 |
2023-01-10 |
Mayo Foundation For Medical Education And Research |
Carrier-PD-L1 binding agent compositions for treating cancers
|
|
EP3506950A1
(en)
|
2016-09-01 |
2019-07-10 |
Mayo Foundation for Medical Education and Research |
Methods and compositions for targeting t-cell cancers
|
|
US11427637B2
(en)
|
2016-09-06 |
2022-08-30 |
Mayo Foundation For Medical Education And Research |
Methods of treating PD-L1 expressing cancer
|
|
US11590098B2
(en)
|
2016-09-06 |
2023-02-28 |
Mayo Foundation For Medical Education And Research |
Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
|
|
EP3509643A1
(en)
|
2016-09-06 |
2019-07-17 |
Mayo Foundation for Medical Education and Research |
Paclitaxel-albumin-binding agent compositions and methods for using and making the same
|
|
US11041014B2
(en)
|
2016-10-28 |
2021-06-22 |
S & K Biopharma, Inc. |
Lactoferrin/albumin fusion protein and production method therefor
|